EGFR T790M is a point mutation in the EGFR gene that is associated with resistance to epidermal growth factor receptor (EGFR) kinase inhibitors like erlotinib and gefitinib. Since its initial discovery in 2005, the T790M mutation has been the subject of much research aiming to better understand drug resistance in non-small cell lung cancer (NSCLC). However, the role of T790M as a biomarker for the clinical care of lung cancer patients over the same time period has been less clear.

Dr. Geoffrey Oxnard describes the new finding of individuals with an inherited T790M mutation in the EGFR gene, the unclear significance of it, and a study being conducted to learn more about it.

[powerpress]